The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
Open accessAbstract
Purpose: Neoadjuvant chemotherapy is established in the management of most resectable esophageal and esophagogastric junction adenocarcinomas. However, assessing the downstaging effects of chemotherapy and predicting response to treatment remain challenging, and the relative importance of tumor stage before and after chemotherapy is debatable. Methods: We analyzed consecutive resections for esophageal or esophagogastric junction adenocarcinomas performed at two high-volume cancer centers in London between 2000 and 2010. After standard investigations and multidisciplinary team consensus, all patients were allocated a clinical tumor stage before treatment, which was compared with pathologic stage after surgical resection. Survival analysis was conducted using Kaplan-Meier analysis and Cox regression analysis. Results: Among 584 included patients, 400 patients (68%) received neoadjuvant chemotherapy. Patients with downstaged tumors after neoadjuvant chemotherapy experienced improved survival compared with patients without response (P < .001), and such downstaging (hazard ratio, 0.43; 95% CI, 0.31 to 0.59) was the strongest independent predictor of survival after adjusting for patient age, tumor grade, clinical tumor stage, lymphovascular invasion, resection margin status, and surgical resection type. Patients downstaged by chemotherapy, compared with patients with no response, experienced lower rates of local recurrence (6% v 13%, respectively; P = .030) and systemic recurrence (19% v 29%, respectively; P = .027) and improved Mandard tumor regression scores (P < .001). Survival was strongly dictated by stage after neoadjuvant chemotherapy, rather than clinical stage at presentation. Conclusion: The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvant chemotherapy determines prognosis rather than the clinical stage before neoadjuvant chemotherapy, indicating the importance of focusing on postchemotherapy staging to more accurately predict outcome and eligibility for surgery. Patients who are downstaged by neoadjuvant chemotherapy benefit from reduced rates of local and systemic recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuyama, J., Doki, Y., Yasuda, T., Miyata, H., Fujiwara, Y., Takiguchi, S., Yamasaki, M., Makari, Y., Matsuura, N., Mano, M., et al. (2007) · Surgery · doi:10.1016/j.surg.2006.11.007 · Cited by 64
Cited by
Lagergren, J., Smyth, E., Cunningham, D., & Lagergren, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31462-9 · Cited by 1,141
Self-citationThe Epidemiology of Esophageal Adenocarcinoma
Coleman, H. G., Xie, S.-H., & Lagergren, J. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.07.046 · Cited by 549
Self-citationCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316
Rice, T. W., Ishwaran, H., Hofstetter, W. L., Kelsen, D. P., Apperson-Hansen, C., Blackstone, E. H., & for the Worldwide Esophageal Cancer Collaboration Investigators (2016) · Diseases of the Esophagus · doi:10.1111/dote.12533 · Cited by 280
Metadata
- Authors
- Davies, A. R., Gossage, J. A., Zylstra, J., Mattsson, F., Lagergren, J., Maisey, N., Smyth, E. C., Cunningham, D., Allum, W. H., & Mason, R. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-09-20
- Volume
- 32
- Issue
- 27
- Pages
- 2983-2990
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161395451
- Cited by
- 246
- References
- 1
- FWCI
- 20.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.